Literature DB >> 8676486

Location, exposure, and conservation of neutralizing and nonneutralizing epitopes on human immunodeficiency virus type 2 SU glycoprotein.

A McKnight1, C Shotton, J Cordell, I Jones, G Simmons, P R Clapham.   

Abstract

Eleven rat monoclonal antibodies (MAbs) that recognize the SU glycoprotein of human immunodeficiency virus type 2 (HIV-2) ROD were produced and characterized. Binding sites for eight of these MAbs were mapped to epitopes within the Cl, V1/V2, C2, and V3 envelope regions. The three other MAbs defined at least two conformation-dependent, strain-specific epitopes outside Vl/V2, V3, and the CD4-binding site. The MAbs were used to probe the tertiary structure of oligomeric envelope glycoprotein expressed on the surfaces of infected cells. Epitopes at the apices of V2 and V3 were exposed on the native molecule, whereas other epitopes on V1/V2, Cl, and C2 were hidden. The MAbs defined three neutralization targets on exposed domains: two linear epitopes in the V2 and the V3 loops and one conformational epitope outside V1, V2, and V3.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8676486      PMCID: PMC190396     

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  76 in total

1.  Antisera raised against the second variable region of the external envelope glycoprotein of human immunodeficiency virus type 1 cross-neutralize and show an increased neutralization index when they act together with antisera to the V3 neutralization epitope.

Authors:  D Davis; D M Stephens; C A Carne; P J Lachmann
Journal:  J Gen Virol       Date:  1993-12       Impact factor: 3.891

2.  Probing the structure of the human immunodeficiency virus surface glycoprotein gp120 with a panel of monoclonal antibodies.

Authors:  J P Moore; Q J Sattentau; R Wyatt; J Sodroski
Journal:  J Virol       Date:  1994-01       Impact factor: 5.103

3.  Characterization of neutralizing monoclonal antibodies to linear and conformation-dependent epitopes within the first and second variable domains of human immunodeficiency virus type 1 gp120.

Authors:  J A McKeating; C Shotton; J Cordell; S Graham; P Balfe; N Sullivan; M Charles; M Page; A Bolmstedt; S Olofsson
Journal:  J Virol       Date:  1993-08       Impact factor: 5.103

4.  Probing the structure of the V2 domain of human immunodeficiency virus type 1 surface glycoprotein gp120 with a panel of eight monoclonal antibodies: human immune response to the V1 and V2 domains.

Authors:  J P Moore; Q J Sattentau; H Yoshiyama; M Thali; M Charles; N Sullivan; S W Poon; M S Fung; F Traincard; M Pinkus
Journal:  J Virol       Date:  1993-10       Impact factor: 5.103

5.  A conserved neutralizing epitope on gp41 of human immunodeficiency virus type 1.

Authors:  T Muster; F Steindl; M Purtscher; A Trkola; A Klima; G Himmler; F Rüker; H Katinger
Journal:  J Virol       Date:  1993-11       Impact factor: 5.103

6.  HIV-2 antibodies in serum samples from Maharashtra state.

Authors:  S Kulkarni; M Thakar; J Rodrigues; K Banerjee
Journal:  Indian J Med Res       Date:  1992-09       Impact factor: 2.375

7.  Two neutralizing domains in the V3 region in the envelope glycoprotein gp125 of HIV type 2.

Authors:  E Björling; F Chiodi; G Utter; E Norrby
Journal:  J Immunol       Date:  1994-02-15       Impact factor: 5.422

8.  Studies of the conformation-dependent neutralizing epitopes of simian immunodeficiency virus envelope protein.

Authors:  K Javaherian; A J Langlois; D C Montefiori; K A Kent; K A Ryan; P D Wyman; J Stott; D P Bolognesi; M Murphey-Corb; G J Larosa
Journal:  J Virol       Date:  1994-04       Impact factor: 5.103

9.  Genetic analysis of human immunodeficiency virus type 1 and 2 (HIV-1 and HIV-2) mixed infections in India reveals a recent spread of HIV-1 and HIV-2 from a single ancestor for each of these viruses.

Authors:  M Grez; U Dietrich; P Balfe; H von Briesen; J K Maniar; G Mahambre; E L Delwart; J I Mullins; H Rübsamen-Waigmann
Journal:  J Virol       Date:  1994-04       Impact factor: 5.103

10.  Further characterization of an antigenic site of HIV-1 gp120 recognized by virus neutralizing human monoclonal antibodies.

Authors:  M Schutten; A McKnight; R C Huisman; M Thali; J A McKeating; J Sodroski; J Goudsmit; A D Osterhaus
Journal:  AIDS       Date:  1993-07       Impact factor: 4.177

View more
  15 in total

1.  Promiscuous use of CC and CXC chemokine receptors in cell-to-cell fusion mediated by a human immunodeficiency virus type 2 envelope protein.

Authors:  R Bron; P J Klasse; D Wilkinson; P R Clapham; A Pelchen-Matthews; C Power; T N Wells; J Kim; S C Peiper; J A Hoxie; M Marsh
Journal:  J Virol       Date:  1997-11       Impact factor: 5.103

2.  Characterization of a late entry event in the replication cycle of human immunodeficiency virus type 2.

Authors:  D J Griffiths; M Dittmar; P Clapham; E Thomas
Journal:  J Virol       Date:  2001-08       Impact factor: 5.103

3.  The CD4-independent tropism of human immunodeficiency virus type 2 involves several regions of the envelope protein and correlates with a reduced activation threshold for envelope-mediated fusion.

Authors:  J D Reeves; T F Schulz
Journal:  J Virol       Date:  1997-02       Impact factor: 5.103

4.  CD4-independent infection by human immunodeficiency virus type 2 strain ROD/B: the role of the N-terminal domain of CXCR-4 in fusion and entry.

Authors:  S Potempa; L Picard; J D Reeves; D Wilkinson; R A Weiss; S J Talbot
Journal:  J Virol       Date:  1997-06       Impact factor: 5.103

5.  Potent and broadly reactive HIV-2 neutralizing antibodies elicited by a vaccinia virus vector prime-C2V3C3 polypeptide boost immunization strategy.

Authors:  José Maria Marcelino; Pedro Borrego; Cheila Rocha; Helena Barroso; Alexandre Quintas; Carlos Novo; Nuno Taveira
Journal:  J Virol       Date:  2010-09-15       Impact factor: 5.103

6.  Inhibition of human immunodeficiency virus fusion by a monoclonal antibody to a coreceptor (CXCR4) is both cell type and virus strain dependent.

Authors:  A McKnight; D Wilkinson; G Simmons; S Talbot; L Picard; M Ahuja; M Marsh; J A Hoxie; P R Clapham
Journal:  J Virol       Date:  1997-02       Impact factor: 5.103

7.  Production, purification, crystallization and preliminary X-ray diffraction analysis of the HIV-2-neutralizing V3 loop-specific Fab fragment 7C8.

Authors:  Hannes Uchtenhagen; Samer Sourial; Rosmarie Friemann; Mariethe Ehnlund; Anna-Lena Spetz; Robert A Harris; Chaithanya Madhurantakam; Adnane Achour
Journal:  Acta Crystallogr Sect F Struct Biol Cryst Commun       Date:  2009-06-27

8.  Primary human immunodeficiency virus type 2 (HIV-2) isolates infect CD4-negative cells via CCR5 and CXCR4: comparison with HIV-1 and simian immunodeficiency virus and relevance to cell tropism in vivo.

Authors:  J D Reeves; S Hibbitts; G Simmons; A McKnight; J M Azevedo-Pereira; J Moniz-Pereira; P R Clapham
Journal:  J Virol       Date:  1999-09       Impact factor: 5.103

9.  Evolutionary and structural features of the C2, V3 and C3 envelope regions underlying the differences in HIV-1 and HIV-2 biology and infection.

Authors:  Helena Barroso; Pedro Borrego; Inês Bártolo; José Maria Marcelino; Carlos Família; Alexandre Quintas; Nuno Taveira
Journal:  PLoS One       Date:  2011-01-20       Impact factor: 3.240

10.  Crystal structure of the HIV-2 neutralizing Fab fragment 7C8 with high specificity to the V3 region of gp125.

Authors:  Hannes Uchtenhagen; Rosmarie Friemann; Grzegorz Raszewski; Anna-Lena Spetz; Lennart Nilsson; Adnane Achour
Journal:  PLoS One       Date:  2011-04-26       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.